Skip to main content
NCBI home page
Occupational and Environmental Medicine logoLink to Occupational and Environmental Medicine
. 1994 Apr;51(4):229–233. doi: 10.1136/oem.51.4.229

Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs.

A S Ensslin 1, Y Stoll 1, A Pethran 1, A Pfaller 1, H Römmelt 1, G Fruhmann 1
PMCID: PMC1127952  PMID: 8199663

Abstract

The occupational exposure of 21 nurses and pharmacy personnel from eight hospitals to cyclophosphamide and ifosfamide was determined by quantifying the amount of the drugs handled and by measuring the urinary excretion of the unmetabolised substances. Preparing antineoplastic drugs for intravenous treatment was the major task of all study participants. Twenty four hour urine was collected on days when cyclophosphamide and/or ifosfamide were mixed, on average 3900 mg cyclophosphamide and/or 5900 mg ifosfamide. The analyses were performed by gas chromatography with electron capture, detection limit 2.5 micrograms/24 hour urine. Despite standard safety precautions, including a vertical laminar air flow safety cabinet and gloves, cyclophosphamide was detected in 12 of 31 and ifosfamide in four of 21 urine samples on days when the drugs were handled. Excretion of cyclophosphamide ranged from 3.5 to 38 micrograms/24 h (mean 11.4 micrograms/24 h) urine, ifosfamide from 5 to 12.7 micrograms/24 h (mean 9 micrograms/24 h) urine. Based on an excretion rate of 11.3% unmetabolised cyclophosphamide, the average amount excreted corresponded to an uptake of 101 micrograms cyclophosphamide. For ifosfamide the mean quantity incorporated was 20 micrograms assuming that 45% of the drug was excreted. Pertaining to the doses handled, the uptake of cyclophosphamide and ifosfamide was estimated to be approximately 0.0025% and 0.0004% respectively. Despite time-consuming purification procedures, gas chromatographic analysis is a suitable method for monitoring personnel occupationally exposed to cyclophosphamide and ifosfamide and is a major contribution to the evaluation of potential health risks of exposed personnel.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker G. L., Kahl L. E., Zee B. C., Stolzer B. L., Agarwal A. K., Medsger T. A., Jr Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med. 1987 Jul;83(1):1–9. doi: 10.1016/0002-9343(87)90490-6. [DOI] [PubMed] [Google Scholar]
  2. Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol. 1982 Dec;9(4 Suppl 1):2–7. [PubMed] [Google Scholar]
  3. Evelo C. T., Bos R. P., Peters J. G., Henderson P. T. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986;58(2):151–155. doi: 10.1007/BF00380766. [DOI] [PubMed] [Google Scholar]
  4. Greene M. H., Boice J. D., Jr, Greer B. E., Blessing J. A., Dembo A. J. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982 Dec 2;307(23):1416–1421. doi: 10.1056/NEJM198212023072302. [DOI] [PubMed] [Google Scholar]
  5. Haas J. F., Kittelmann B., Mehnert W. H., Staneczek W., Möhner M., Kaldor J. M., Day N. E. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987 Feb;55(2):213–218. doi: 10.1038/bjc.1987.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hemminki K., Kyyrönen P., Lindbohm M. L. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985 Jun;39(2):141–147. doi: 10.1136/jech.39.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hirst M., Tse S., Mills D. G., Levin L., White D. F. Occupational exposure to cyclophosphamide. Lancet. 1984 Jan 28;1(8370):186–188. doi: 10.1016/s0140-6736(84)92111-1. [DOI] [PubMed] [Google Scholar]
  8. Jagun O., Ryan M., Waldron H. A. Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet. 1982 Aug 21;2(8295):443–444. doi: 10.1016/s0140-6736(82)90474-3. [DOI] [PubMed] [Google Scholar]
  9. Jardine I., Fenselau C., Appler M., Kan M. N., Brundrett R. B., Colvin M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res. 1978 Feb;38(2):408–415. [PubMed] [Google Scholar]
  10. Laidlaw J. L., Connor T. H., Theiss J. C., Anderson R. W., Matney T. S. Permeability of latex and polyvinyl chloride gloves to 20 antineoplastic drugs. Am J Hosp Pharm. 1984 Dec;41(12):2618–2623. [PubMed] [Google Scholar]
  11. Martino R., Malet-Martino M. C., Armand J. P., De Forni M. Potentialities de la RMN du fluor-19 et du phosphore-31 pour l'etude du metabolisme et de la pharmacocinetique d'agents antitumoraux fluorés ou phosphorés. Bull Cancer. 1989;76(8):859–861. [PubMed] [Google Scholar]
  12. McDevitt J. J., Lees P. S., McDiarmid M. A. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993 Jan;35(1):57–60. [PubMed] [Google Scholar]
  13. McDonald A. D., McDonald J. C., Armstrong B., Cherry N. M., Côté R., Lavoie J., Nolin A. D., Robert D. Congenital defects and work in pregnancy. Br J Ind Med. 1988 Sep;45(9):581–588. doi: 10.1136/oem.45.9.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Oestreicher U., Stephan G., Glatzel M. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat Res. 1990 Dec;242(4):271–277. doi: 10.1016/0165-1218(90)90045-4. [DOI] [PubMed] [Google Scholar]
  15. Pedersen-Bjergaard J., Ersbøll J., Sørensen H. M., Keiding N., Larsen S. O., Philip P., Larsen M. S., Schultz H., Nissen N. I. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985 Aug;103(2):195–200. doi: 10.7326/0003-4819-103-2-195. [DOI] [PubMed] [Google Scholar]
  16. Pyy L., Sorsa M., Hakala E. Ambient monitoring of cyclophosphamide in manufacture and hospitals. Am Ind Hyg Assoc J. 1988 Jun;49(6):314–317. doi: 10.1080/15298668891379800. [DOI] [PubMed] [Google Scholar]
  17. Selevan S. G., Lindbohm M. L., Hornung R. W., Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985 Nov 7;313(19):1173–1178. doi: 10.1056/NEJM198511073131901. [DOI] [PubMed] [Google Scholar]
  18. Sessink P. J., Boer K. A., Scheefhals A. P., Anzion R. B., Bos R. P. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992;64(2):105–112. doi: 10.1007/BF00381477. [DOI] [PubMed] [Google Scholar]
  19. Skov T., Lynge E., Maarup B., Olsen J., Rørth M., Winthereik H. Risks for physicians handling antineoplastic drugs. Lancet. 1990 Dec 8;336(8728):1446–1446. doi: 10.1016/0140-6736(90)93148-i. [DOI] [PubMed] [Google Scholar]
  20. Skov T., Maarup B., Olsen J., Rørth M., Winthereik H., Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992 Dec;49(12):855–861. doi: 10.1136/oem.49.12.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Slevin M. L., Ang L. M., Johnston A., Turner P. The efficiency of protective gloves used in the handling of cytotoxic drugs. Cancer Chemother Pharmacol. 1984;12(3):151–153. doi: 10.1007/BF00256536. [DOI] [PubMed] [Google Scholar]
  22. Sorsa M., Pyy L., Salomaa S., Nylund L., Yager J. W. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res. 1988 Mar;204(3):465–479. doi: 10.1016/0165-1218(88)90042-0. [DOI] [PubMed] [Google Scholar]
  23. Stoikes M. E., Carlson J. D., Farris F. F., Walker P. R. Permeability of latex and polyvinyl chloride gloves to fluorouracil and methotrexate. Am J Hosp Pharm. 1987 Jun;44(6):1341–1346. [PubMed] [Google Scholar]
  24. Stücker I., Caillard J. F., Collin R., Gout M., Poyen D., Hémon D. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health. 1990 Apr;16(2):102–107. doi: 10.5271/sjweh.1811. [DOI] [PubMed] [Google Scholar]
  25. Thiringer G., Granung G., Holmén A., Högstedt B., Järvholm B., Jönsson D., Persson L., Wahlström J., Westin J. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health. 1991 Apr;17(2):133–138. doi: 10.5271/sjweh.1724. [DOI] [PubMed] [Google Scholar]
  26. Valanis B., Vollmer W. M., Labuhn K., Glass A., Corelle C. Antineoplastic drug handling protection after OSHA guidelines. Comparison by profession, handling activity, and work site. J Occup Med. 1992 Feb;34(2):149–155. doi: 10.1097/00043764-199202000-00014. [DOI] [PubMed] [Google Scholar]

Articles from Occupational and Environmental Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES